KIMBERLY SCHIFF: Open Payments
NPI 1538630918 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$816 in 29 payments from 10 companies in 2025. Trend: 2023 $691 · 2024 $307 · 2025 $816
Food & beverage: $816
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $280 |
| Incyte Corporation | 1 | $133 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Daiichi Sankyo Inc. | 5 | $99 |
| ABBVIE INC. | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 1 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| JAZZ PHARMACEUTICALS INC. | 1 | $27 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Celgene Corporation | 1 | $17 |
Products named: Fabhalta, Niktimvo, CALQUENCE, Vanflyta, VENCLEXTA, GIVLAARI, SCEMBLIX, ICLUSIG.
Industry payments across CA — which companies pay providers there.
